The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -13,063,512 |
| Stock-based compensation | 618,974 |
| Change in fair value of derivative liabilities | 38,189 |
| Prepaid expenses and other receivable | -431,188 |
| Accounts payable - related party | 550,346 |
| Other payables and accrued liabilities | 36,654 |
| Accrued liability - related party | 9,606,666 |
| Franchise tax payable | -4,134 |
| Income tax payables | -50 |
| Net cash used in operating activities | -1,785,679 |
| Payments of transactions cost | 117,473 |
| Proceeds from issuance of common stock for pipe investment | 2,400,000 |
| Purchase of treasury stock | 29,462 |
| Net cash provided by (used in) financing activities | 2,253,065 |
| Net change in cash | 467,386 |
| Cash at beginning of the year | 916,916 |
| Cash at end of the year | 1,384,302 |
Estrella Immunopharma, Inc. (ESLA)
Estrella Immunopharma, Inc. (ESLA)